Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Pacira Pharma target raised to $59 at H.C. Wainwright (49.55)H.C. Wainwright raises their PCRX tgt to $59 from $48. Given the positive findings announced in TKA, firm raises tgt, as this has further de-risked the stock in their view. The new tgt is derived from a standard discounted cash flow analysis with cash flows projected through 2021, utilizing a 13% (down from previous 15%) discount rate applied to both the cash flows and terminal value, and a 2% terminal growth rate. Risks include: failure to succeed in multiple clinical trials reading out this year, a failure to regain hospital formulary access, and/or unforeseen competitive dynamics either from another branded competitor or generic challengers.</td> </tr></table>"